Hemispherx Biopharma, Inc. to Present at the 4th Annual Maxim Group Growth Conference
16. November 2010 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 16, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), an advanced specialty pharmaceutical company engaged in the clinical development of new drug...
Hemispherx Biopharma, Inc. to Discuss Third Quarter Results of Operations on Tuesday, November 16, 2010
11. November 2010 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 11, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), an advanced specialty pharmaceutical company engaged in the clinical development of new drug...
Hemispherx Biopharma Receives Therapeutic Discovery Project Grant From U.S. Department of Treasury
10. November 2010 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 10, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced today grant awards totaling $488,958 from the U.S. Department of Treasury in support of its...
Hemispherx Biopharma, Inc. 3rd Quarter 2010 Financial Results
08. November 2010 16:49 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Nov. 8, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced its financial results for the three months ended September 30, 2010. The net loss (including...
Hemispherx Biopharma to Present at the Rodman and Renshaw 12th Annual Healthcare Conference
08. September 2010 16:46 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Sept. 8, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) (the "Company"), today announced that the Company will participate in the Rodman & Renshaw 12th Annual...
Hemispherx Biopharma to Present New Retrovirus (XMRV) Data at 1st International Workshop on XMRV and Chronic Fatigue Syndrome (CFS)
08. September 2010 10:23 ET
|
Hemispherx Biopharma, Inc.
BETHESDA, Md., Sept. 8, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) will present new clinical data on the possible inter-relationships of XMRV positivity/chronic fatigue...
Hemispherx Settles All Securities Class Actions
24. August 2010 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 24, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) today announced that, as result of court mediation proceedings, it has entered into a written agreement in...
Hemispherx Biopharma Awarded $188 Million Judgment Against JCI
18. August 2010 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 18, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (AMEX:HEB) today announced that its six-year litigation battle with the South African investment conglomerate JCI Ltd.,...
Hemispherx Biopharma, Inc. 2nd Quarter 2010 Financial Results
06. August 2010 15:16 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, Aug. 6, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB) announced its financial results for the three months ended June 30, 2010. The net loss (including non-cash...
The Indian Drugs Controller General Approves Start of Clinical Study of Hemispherx Biopharma's Natural Interferon Product, Alferon N Injection(R), in Hospitalized Flu Patients
19. Juli 2010 08:00 ET
|
Hemispherx Biopharma, Inc.
PHILADELPHIA, July 19, 2010 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE Amex:HEB), an advanced specialty pharmaceutical company engaged in the clinical development of new drug entities for...